323 related articles for article (PubMed ID: 30842242)
21. [Laryngeal Recurrent Respiratory Papillomatosis: Current Aspects on Diagnosis and Therapy].
Langer C; Wittekindt C; Wolf G
Laryngorhinootologie; 2019 Aug; 98(8):577-587. PubMed ID: 31387134
[TBL] [Abstract][Full Text] [Related]
22. The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.
Ahn J; Bishop JA; Roden RBS; Allen CT; Best SRA
Laryngoscope; 2018 Jan; 128(1):E27-E32. PubMed ID: 28940446
[TBL] [Abstract][Full Text] [Related]
23. Tracheal papillomatosis: what do we know so far?
Harris K; Chalhoub M
Chron Respir Dis; 2011; 8(4):233-5. PubMed ID: 21971565
[TBL] [Abstract][Full Text] [Related]
24. Molecular transformation of recurrent respiratory papillomatosis: viral typing and p53 overexpression.
Go C; Schwartz MR; Donovan DT
Ann Otol Rhinol Laryngol; 2003 Apr; 112(4):298-302. PubMed ID: 12731623
[TBL] [Abstract][Full Text] [Related]
25. Systemic bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in children: A series of three pediatric cases and literature review.
Enrique OH; Eloy SH; Adrian TP; Perla V
Am J Otolaryngol; 2021; 42(5):103126. PubMed ID: 34175693
[TBL] [Abstract][Full Text] [Related]
26. Profiling of VEGF Receptors and Immune Checkpoints in Recurrent Respiratory Papillomatosis.
Lam B; Miller J; Kung YJ; Wu TC; Hung CF; Roden RBS; Best SR
Laryngoscope; 2024 Jun; 134(6):2819-2825. PubMed ID: 38193541
[TBL] [Abstract][Full Text] [Related]
27. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
28. [Recurrent respiratory papillomatosis: indication for HPV vaccination?].
Pawlita M; Gissmann L
Dtsch Med Wochenschr; 2009 Apr; 134 Suppl 2():S100-2. PubMed ID: 19353471
[TBL] [Abstract][Full Text] [Related]
29. [Research status of human papillomavirus vaccine for prevention and treatment of respiratory papillomatosis].
Pan XF; Wang J; Xiao Y
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Feb; 33(2):189-192. PubMed ID: 30808153
[TBL] [Abstract][Full Text] [Related]
30. The tumor microenvironment state associates with response to HPV therapeutic vaccination in patients with respiratory papillomatosis.
Norberg SM; Bai K; Sievers C; Robbins Y; Friedman J; Yang X; Kenyon M; Ward E; Schlom J; Gulley J; Lankford A; Semnani R; Sabzevari H; Brough DE; Allen CT
Sci Transl Med; 2023 Oct; 15(719):eadj0740. PubMed ID: 37878675
[TBL] [Abstract][Full Text] [Related]
31. Low-Dose Cisplatin-Based Radiation Therapy for Refractory Recurrent Respiratory Papillomatosis.
Takatsuki E; Kono T; Tomisato S; Ozawa H
Laryngoscope; 2024 May; 134(5):2335-2337. PubMed ID: 37812337
[TBL] [Abstract][Full Text] [Related]
32. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
Raggi D; Necchi A; Giannatempo P
Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
[TBL] [Abstract][Full Text] [Related]
33. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution's Experience.
So RJ; Rayle C; Joo HH; Huang EY; Seiwert TY; Raabe EH; Best SR
Laryngoscope; 2024 Jul; 134(7):3253-3259. PubMed ID: 38525973
[TBL] [Abstract][Full Text] [Related]
34. T(H)2-like chemokine patterns correlate with disease severity in patients with recurrent respiratory papillomatosis.
Rosenthal DW; DeVoti JA; Steinberg BM; Abramson AL; Bonagura VR
Mol Med; 2012 Dec; 18(1):1338-45. PubMed ID: 23019074
[TBL] [Abstract][Full Text] [Related]
35. Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis.
Kimberlin DW
Antiviral Res; 2004 Sep; 63(3):141-51. PubMed ID: 15451182
[TBL] [Abstract][Full Text] [Related]
36. Immunological tolerance of low-risk HPV in recurrent respiratory papillomatosis.
Ivancic R; Iqbal H; deSilva B; Pan Q; Matrka L
Clin Exp Immunol; 2020 Feb; 199(2):131-142. PubMed ID: 31628850
[TBL] [Abstract][Full Text] [Related]
37. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
38. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
39. Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis.
Robbins Y; Friedman J; Clavijo PE; Sievers C; Bai K; Donahue RN; Schlom J; Sinkoe A; Hinrichs CS; Allen C; Abdul Sater H; Gulley JL; Norberg S
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34462327
[TBL] [Abstract][Full Text] [Related]
40. Recurrent respiratory papillomatosis.
Venkatesan NN; Pine HS; Underbrink MP
Otolaryngol Clin North Am; 2012 Jun; 45(3):671-94, viii-ix. PubMed ID: 22588043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
